$INSILICO(03696.HK)

The recent surge over the past couple of days is due to several factors: Rentosertib entering Phase III clinical trials, with the core drug moving into late-stage validation; a positive profit forecast for mid-2026, indicating the business model is starting to generate revenue and profits; and consecutive collaborations with companies like Lilly, SK, and Takeda, which validate the platform's value among major pharmaceutical firms. After the lock-up pressure, the stock price didn't collapse but was instead absorbed by capital, restoring market confidence.

Revaluing from an "AI drug discovery concept stock" to an "AI drug discovery platform biotech." 😃